Previous close | 8.10 |
Open | 8.10 |
Bid | 6.20 |
Ask | 6.40 |
Strike | 50.00 |
Expiry date | 2024-12-20 |
Day's range | 8.10 - 8.10 |
Contract range | N/A |
Volume | |
Open interest | 421 |
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.
(Bloomberg) -- Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder, according to people with knowledge of the matter. Most Read from BloombergSingapore Ends 181 Years of Horse Racing to Make Way for HomesFrom Cleveland to Chicago, NFL Teams Dream of Domed StadiumsWhat Do US Vehicle Regulators Have Against Tiny Cars?For a Master of Brutalist Provocations, a Modest Museum Apprais